Royce & Associates’s Amicus Therapeutics FOLD Stock Holding History

Royce & Associates’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-105,300	Closed	-$1.02M	–	1109
2015 Q4	$1.02M	Sell	105,300 -228,700	-68%	-$2.06M	0.01%	932
2015 Q3	$4.67M	Sell	334,000 -46,000	-12%	-$721K	0.02%	663
2015 Q2	$5.38M	Buy	+380,000	New	+$4.57M	0.02%	716
2014 Q3	–	Sell	-283,700	Closed	-$948K	–	1413
2014 Q2	$948K	Sell	283,700 -30,000	-10%	-$70.4K	﹤0.01%	1153
2014 Q1	$649K	Sell	313,700 -42,000	-12%	-$105K	﹤0.01%	1200
2013 Q4	$836K	Sell	355,700 -160,000	-31%	-$351K	﹤0.01%	1190
2013 Q3	$1.2M	Sell	515,700 -200,000	-28%	-$502K	﹤0.01%	1152
2013 Q2	$1.67M	Buy	+715,700	New	+$2.2M	0.01%	1081

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates's FOLD Position: Q1 2016 in Review

Royce & Associates sold out of Amicus Therapeutics (FOLD) in Q1 2016, closing a stake of 105,300 shares — an estimated $1.02M sold.

Royce & Associates first reported a position in FOLD in Q2 2013 and held it in 8 quarters. The position peaked at $5.38M in Q2 2015. 128 funds tracked by Wall St. Rank hold FOLD as of Q1 2016.

Royce & Associates reported no remaining Amicus Therapeutics position as of Q1 2016 after selling out during the quarter.
Royce & Associates sold 105,300 Amicus Therapeutics shares in Q1 2016, an estimated $1.02M.
Royce & Associates first reported a position in Amicus Therapeutics in Q2 2013 and held it in 8 quarters.
Royce & Associates's Amicus Therapeutics position peaked at $5.38M in Q2 2015.
128 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2016.

Based on Royce & Associates's 13F filing for Q1 2016, filed 11 May 2016.